SI-BONE Inc
NASDAQ:SIBN
Intrinsic Value
SI-BONE, Inc. engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. [ Read More ]
The intrinsic value of one SIBN stock under the Base Case scenario is 22.36 USD. Compared to the current market price of 15.82 USD, SI-BONE Inc is Undervalued by 29%.
Valuation Backtest
SI-BONE Inc
Run backtest to discover the historical profit from buying and selling SIBN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
SI-BONE Grows Revenue by 31% in 2023
2023-Q4 Earnings Call
SI-BONE had an outstanding 2023, driven by strong U.S. demand, resulting in a record $138.9 million in worldwide revenue, a significant beat over the initial forecast of $124-$127 million, and marking a 31% year-over-year growth. U.S. physicians were key contributors, performing over 15,000 procedures. The company's focused investments in scalable operations led to a substantial 48% improvement in adjusted EBITDA. Continuing the positive trend, the annual procedure volume growth rate in the U.S. hit 25% and revenue per U.S. territory surged 39% to $1.6 million. With a thriving physician engagement, SI-BONE is now targeting nearly 0.5 million annual sacropelvic procedures as they plan for an eventful 2024 with new product launches and further market penetration.
Balance Sheet Decomposition
SI-BONE Inc
Current Assets | 211.4m |
Cash & Short-Term Investments | 166m |
Receivables | 22m |
Other Current Assets | 23.4m |
Non-Current Assets | 19m |
PP&E | 18.7m |
Other Non-Current Assets | 325k |
Current Liabilities | 23.5m |
Accounts Payable | 4.6m |
Accrued Liabilities | 18.9m |
Non-Current Liabilities | 37.6m |
Long-Term Debt | 36.1m |
Other Non-Current Liabilities | 1.5m |
Earnings Waterfall
SI-BONE Inc
Revenue
|
138.9m
USD
|
Cost of Revenue
|
-29.5m
USD
|
Gross Profit
|
109.4m
USD
|
Operating Expenses
|
-156.4m
USD
|
Operating Income
|
-46.9m
USD
|
Other Expenses
|
3.6m
USD
|
Net Income
|
-43.3m
USD
|
Free Cash Flow Analysis
SI-BONE Inc
What is Free Cash Flow?
SIBN Profitability Score
Profitability Due Diligence
SI-BONE Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
SI-BONE Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
SIBN Solvency Score
Solvency Due Diligence
SI-BONE Inc's solvency score is 85/100. The higher the solvency score, the more solvent the company is.
Score
SI-BONE Inc's solvency score is 85/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SIBN Price Targets Summary
SI-BONE Inc
According to Wall Street analysts, the average 1-year price target for SIBN is 27.41 USD with a low forecast of 24.24 USD and a high forecast of 33.6 USD.
Ownership
SIBN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
SIBN Price
SI-BONE Inc
Average Annual Return | -2.55% |
Standard Deviation of Annual Returns | 35.73% |
Max Drawdown | -69% |
Market Capitalization | 640.7m USD |
Shares Outstanding | 41 064 500 |
Percentage of Shares Shorted | 6.35% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
SI-BONE, Inc. engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. The company is headquartered in Santa Clara, California and currently employs 352 full-time employees. The company went IPO on 2018-10-17. The firm is focused on the development of implantable devices used in the surgical treatment of sacro-pelvic anatomy. Its invasive surgical implant system, iFuse, is used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. Its iFuse Implant System includes a series of triangular titanium implants and the instruments developed to enable surgeons to perform the procedure. Its iFuse system, which includes its implants and instruments, is designed to address the shortcomings of alternative treatments, including open surgery, non-surgical management, and screw-based and other minimally invasive stabilization and fusion procedures. Its iFuse-3D design allows the surgeons to fill the implant with ground-up bone before implantation, which accelerates bone through-growth and biological fixation. The company also provides other technologies for its surgeons other than iFuse and iFuse-3D.
Contact
IPO
Employees
Officers
The intrinsic value of one SIBN stock under the Base Case scenario is 22.36 USD.
Compared to the current market price of 15.82 USD, SI-BONE Inc is Undervalued by 29%.